Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamnorzatinib in Acute Leukemias or Myelodysplastic Syndromes
NCT03176277Phase 2Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2017
- Primary completion
- Dec 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ONO-7475 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Ono Pharmaceutical. Started Jun 2017; status: terminated.
02
Drugs
ONO-7475
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03176277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03176277.